Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aclaris Therapeutics, Inc.ACRS · Entity 5041 | Chief Business Officer | February 02, 2026 | February 06, 2026 |
| Anika Therapeutics, Inc.ANIK · Entity 6005 | EVP Business Development | July 08, 2021 | July 12, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aclaris Therapeutics, Inc.
Report date February 02, 2026 · Filed February 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 97,700 |
Reported balance
After 2026-02-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-02 · Grant · Acquired 97,700 · Balance 97,700 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.61 · Expires 2036-02-01 | Direct | 341,900 |
Reported balance
After 2026-02-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-02 · Grant · Acquired 341,900 · Balance 341,900 F3: Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.
F3: Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.
Anika Therapeutics, Inc.
Report date July 08, 2021 · Filed July 12, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,592 |
Ending reported balance
After 2021-07-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-07-08 · Exercise / conversion · Acquired 3,000 · Balance 6,323 F1: Reflects the second vesting installment of RSUs granted on July 8, 2019. Row 2 · 2021-07-08 · Tax withholding · Disposed 731 · Balance 5,592 F2: Reflects an aggregate of 731 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on July 8, 2021. F3: Reflects the closing price of ANIK common stock on July 8, 2021, the trading day on which the vesting of RSUs gave rise to tax withholding obligations. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 3,000 |
Reported balance
After 2021-07-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-07-08 · Exercise / conversion · Acquired 3,000 · Balance 3,000 F1: Reflects the second vesting installment of RSUs granted on July 8, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the second vesting installment of RSUs granted on July 8, 2019.
F2: Reflects an aggregate of 731 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on July 8, 2021.
F3: Reflects the closing price of ANIK common stock on July 8, 2021, the trading day on which the vesting of RSUs gave rise to tax withholding obligations.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 03, 2026 Filed Feb 5, 2026 16:48 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 20,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001781549-26-000011 · form4-02052026_090237.xml · derivative · entry 3 Loerop James · CIK 0001781549 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,625 Underlying: Common Stock · 20,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. F3 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 16:48 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 5,937 | $3.47 | $20,601.39 |
DisclosureSEC source: 0001781549-26-000011 · form4-02052026_090237.xml · nonDerivative · entry 2 Loerop James · CIK 0001781549 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 192,260 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 16:48 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 20,875 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001781549-26-000011 · form4-02052026_090237.xml · nonDerivative · entry 1 Loerop James · CIK 0001781549 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 198,197 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| February 02, 2026 Filed Feb 6, 2026 18:02 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantEmployee Stock Option (Right to Buy) · Derivative | 341,900 | $0.00 Strike: $3.61 | $0.00 |
DisclosureSEC source: 0001781549-26-000013 · form4-02062026_110255.xml · derivative · entry 2 Loerop James · CIK 0001781549 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 341,900 Underlying: Common Stock · 341,900 shares Expires 2036-02-01 F3 · derivative.exercise_date: Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| February 02, 2026 Filed Feb 6, 2026 18:02 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted Stock Units · Derivative | 97,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001781549-26-000013 · form4-02062026_110255.xml · derivative · entry 1 Loerop James · CIK 0001781549 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,700 Underlying: Common Stock · 97,700 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. F2 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| February 01, 2026 Filed Feb 5, 2026 16:38 UTC Amendment | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 14,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001781549-26-000009 · form4a-02052026_090200.xml · derivative · entry 7 Loerop James · CIK 0001781549 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,500 Underlying: Common Stock · 14,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. F5 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| February 01, 2026 Filed Feb 5, 2026 16:38 UTC Amendment | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionResticted Stock Units · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001781549-26-000009 · form4a-02052026_090200.xml · derivative · entry 6 Loerop James · CIK 0001781549 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F4 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| February 01, 2026 Filed Feb 5, 2026 16:38 UTC Amendment | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 11,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001781549-26-000009 · form4a-02052026_090200.xml · derivative · entry 5 Loerop James · CIK 0001781549 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2022, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. F3 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2022, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| February 01, 2026 Filed Feb 5, 2026 16:38 UTC Amendment | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 10,686 | $3.51 | $37,507.86 |
DisclosureSEC source: 0001781549-26-000009 · form4a-02052026_090200.xml · nonDerivative · entry 4 Loerop James · CIK 0001781549 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 177,322 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. Read SEC document |
| February 01, 2026 Filed Feb 5, 2026 16:38 UTC Amendment | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 14,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001781549-26-000009 · form4a-02052026_090200.xml · nonDerivative · entry 3 Loerop James · CIK 0001781549 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 188,008 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| February 01, 2026 Filed Feb 5, 2026 16:38 UTC Amendment | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 7,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001781549-26-000009 · form4a-02052026_090200.xml · nonDerivative · entry 2 Loerop James · CIK 0001781549 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 173,258 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| February 01, 2026 Filed Feb 5, 2026 16:38 UTC Amendment | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 11,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001781549-26-000009 · form4a-02052026_090200.xml · nonDerivative · entry 1 Loerop James · CIK 0001781549 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,758 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 16:30 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 18,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001781549-26-000003 · form4-01052026_090101.xml · derivative · entry 6 Loerop James · CIK 0001781549 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,700 Underlying: Common Stock · 18,150 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F4 · derivative.exercise_date: The shares underlying these restricted stock units vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 16:30 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 6,171 | $2.88 | $17,772.48 |
DisclosureSEC source: 0001781549-26-000003 · form4-01052026_090101.xml · nonDerivative · entry 4 Loerop James · CIK 0001781549 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,041 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 16:30 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 18,150 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001781549-26-000003 · form4-01052026_090101.xml · nonDerivative · entry 3 Loerop James · CIK 0001781549 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,212 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 16:30 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 73,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001781549-26-000003 · form4-01052026_090101.xml · derivative · entry 5 Loerop James · CIK 0001781549 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 73,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F3 · derivative.exercise_date: 50% of the shares underlying these restricted stock units vested on each of December 31, 2024 and December 31, 2025. F3 · derivative.expiration_date: 50% of the shares underlying these restricted stock units vested on each of December 31, 2024 and December 31, 2025. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 16:30 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 33,994 | $3.01 | $102,321.94 |
DisclosureSEC source: 0001781549-26-000003 · form4-01052026_090101.xml · nonDerivative · entry 2 Loerop James · CIK 0001781549 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,062 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 16:30 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 73,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001781549-26-000003 · form4-01052026_090101.xml · nonDerivative · entry 1 Loerop James · CIK 0001781549 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 177,056 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 16:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantEmployee Stock Option (Right to Buy) · Derivative | 292,300 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001415889-25-002938 · form4-02042025_040201.xml · derivative · entry 9 Loerop James · CIK 0001781549 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 292,300 Underlying: Common Stock · 292,300 shares Expires 2035-02-02 F7 · derivative.exercise_date: Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 16:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted Stock Units · Derivative | 83,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-002938 · form4-02042025_040201.xml · derivative · entry 8 Loerop James · CIK 0001781549 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,500 Underlying: Common Stock · 83,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F6 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. F6 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 16:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 14,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-002938 · form4-02042025_040201.xml · derivative · entry 7 Loerop James · CIK 0001781549 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,250 Underlying: Common Stock · 14,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F5 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. F5 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 16:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionResticted Stock Units · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-002938 · form4-02042025_040201.xml · derivative · entry 6 Loerop James · CIK 0001781549 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 7,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F4 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 16:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 11,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-002938 · form4-02042025_040201.xml · derivative · entry 5 Loerop James · CIK 0001781549 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,250 Underlying: Common Stock · 11,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2022, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. F3 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2022, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 16:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 15,447 | $2.48 | $38,308.56 |
DisclosureSEC source: 0001415889-25-002938 · form4-02042025_040201.xml · nonDerivative · entry 4 Loerop James · CIK 0001781549 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,306 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 16:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 14,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-002938 · form4-02042025_040201.xml · nonDerivative · entry 3 Loerop James · CIK 0001781549 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,753 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 16:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 7,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-002938 · form4-02042025_040201.xml · nonDerivative · entry 2 Loerop James · CIK 0001781549 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,003 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 16:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 11,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-002938 · form4-02042025_040201.xml · nonDerivative · entry 1 Loerop James · CIK 0001781549 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,503 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| February 01, 2025 Filed Feb 3, 2026 17:34 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 15,980 | $2.48 | $39,630.40 |
DisclosureSEC source: 0001781549-26-000007 · form4-02032026_100229.xml · nonDerivative · entry 1 Loerop James · CIK 0001781549 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,773 F1 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. F2 · balance_after: This amendment is being filed to correct the number of shares that were withheld by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units previously reported. This adjustment will affect the amount of securities beneficially owned following the reported transaction in subsequent filings. Read SEC document |
| February 01, 2025 Filed Feb 3, 2026 17:32 UTC Amendment | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 15,980 | $2.48 | $39,630.40 |
DisclosureSEC source: 0001781549-26-000005 · form4a-02032026_100202.xml · nonDerivative · entry 1 Loerop James · CIK 0001781549 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,773 F1 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. F2 · balance_after: This amendment is being filed to correct the number of shares that were withheld by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units previously reported. This adjustment will affect the amount of securities beneficially owned following the reported transaction in subsequent filings. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 18:25 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 18,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000622 · form4-01032025_060104.xml · derivative · entry 7 Loerop James · CIK 0001781549 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,850 Underlying: Common Stock · 18,150 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F4 · derivative.exercise_date: The shares underlying these restricted stock units vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 18:25 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted Stock Units · Derivative | 55,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000622 · form4-01032025_060104.xml · derivative · entry 6 Loerop James · CIK 0001781549 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F4 · derivative.exercise_date: The shares underlying these restricted stock units vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 18:25 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 8,575 | $2.48 | $21,266.00 |
DisclosureSEC source: 0001415889-25-000622 · form4-01032025_060104.xml · nonDerivative · entry 4 Loerop James · CIK 0001781549 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,253 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 18:25 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 18,150 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-000622 · form4-01032025_060104.xml · nonDerivative · entry 3 Loerop James · CIK 0001781549 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,828 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 18:25 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 73,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000622 · form4-01032025_060104.xml · derivative · entry 5 Loerop James · CIK 0001781549 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,750 Underlying: Common Stock · 73,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F3 · derivative.exercise_date: 50% of the shares underlying these restricted stock units vested or will vest on each of December 31, 2024 and December 31, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. F3 · derivative.expiration_date: 50% of the shares underlying these restricted stock units vested or will vest on each of December 31, 2024 and December 31, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 18:25 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 32,089 | $2.48 | $79,580.72 |
DisclosureSEC source: 0001415889-25-000622 · form4-01032025_060104.xml · nonDerivative · entry 2 Loerop James · CIK 0001781549 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,678 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 18:25 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 73,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-000622 · form4-01032025_060104.xml · nonDerivative · entry 1 Loerop James · CIK 0001781549 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,767 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 19:29 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted Stock Units · Derivative | 147,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-002838 · doc4.xml · derivative · entry 9 Loerop James · CIK 0001781549 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,500 Underlying: Common Stock · 147,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F7 · derivative.exercise_date: 50% of the shares underlying these restricted stock units vest on each of December 31, 2024 and December 31, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. F7 · derivative.expiration_date: 50% of the shares underlying these restricted stock units vest on each of December 31, 2024 and December 31, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 19:29 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted Stock Units · Derivative | 59,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-002838 · doc4.xml · derivative · entry 8 Loerop James · CIK 0001781549 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,000 Underlying: Common Stock · 59,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F6 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. F6 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 19:29 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantEmployee Stock Option (Right to Buy) · Derivative | 206,500 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001209191-24-002838 · doc4.xml · derivative · entry 7 Loerop James · CIK 0001781549 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 206,500 Underlying: Common Stock · 206,500 shares Expires 2034-01-31 F5 · derivative.exercise_date: Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 19:29 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Unit · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-002838 · doc4.xml · derivative · entry 6 Loerop James · CIK 0001781549 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 7,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F4 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 19:29 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 11,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-002838 · doc4.xml · derivative · entry 5 Loerop James · CIK 0001781549 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 11,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2022, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. F3 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2022, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 19:29 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 2,568 | $1.20 | $3,081.60 |
DisclosureSEC source: 0001209191-24-002838 · doc4.xml · nonDerivative · entry 4 Loerop James · CIK 0001781549 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,017 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 19:29 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 7,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-24-002838 · doc4.xml · nonDerivative · entry 3 Loerop James · CIK 0001781549 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,585 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 19:29 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 3,853 | $1.20 | $4,623.60 |
DisclosureSEC source: 0001209191-24-002838 · doc4.xml · nonDerivative · entry 2 Loerop James · CIK 0001781549 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,085 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 19:29 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 11,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-24-002838 · doc4.xml · nonDerivative · entry 1 Loerop James · CIK 0001781549 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,938 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| August 28, 2023 Filed Aug 28, 2023 16:39 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | PurchaseCommon Stock | 14,705 | $6.80 | $99,958.71 |
DisclosureSEC source: 0001209191-23-047522 · doc4.xml · nonDerivative · entry 1 Loerop James · CIK 0001781549 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,688 F1 · price: The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $6.7699 to $6.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| February 08, 2023 Filed Feb 10, 2023 16:55 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 4,267 | $13.89 | $59,272.47 |
DisclosureSEC source: 0001209191-23-008451 · doc4.xml · nonDerivative · entry 1 Loerop James · CIK 0001781549 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,983 F1 · kind: Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on February 1, 2023 pursuant to preexisting sell-to-cover elections. F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $13.80 to $13.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 17:01 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 11,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006999 · doc4.xml · derivative · entry 4 Loerop James · CIK 0001781549 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,750 Underlying: Common Stock · 11,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F4 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2023, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. F4 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2023, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 17:01 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted Stock Units · Derivative | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006999 · doc4.xml · derivative · entry 3 Loerop James · CIK 0001781549 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date. F3 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 17:01 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantEmployee Stock Option (Right to Buy) · Derivative | 105,000 | $0.00 Strike: $16.97 | $0.00 |
DisclosureSEC source: 0001209191-23-006999 · doc4.xml · derivative · entry 2 Loerop James · CIK 0001781549 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires 2033-01-31 F2 · derivative.exercise_date: Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.